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INTRODUCTION
The drug rash with eosinophilia and systemic symptoms 
(DRESS) syndrome, previously referred to as the ‘drug hyper-
sensitivity syndrome’ , is an adverse drug reaction characterized 
by skin rash, fever, lymph-node enlargement and internal organ 
involvement.
1 The definition of DRESS is flawed in that it does 
not characterize the nature of the cutaneous rash. Aromatic an-
ticonvulsants (phenytoin, phenobarbital, carbamazepine) and 
sulfonamides are the most common causes of DRESS.
2
The differential diagnosis includes Stevens-Johnson syndrome 
(SJS), which is a rare, life-threatening, cutaneous adverse reac-
tion. SJS is characterized by targetoid cutaneous lesions affect-
ing less than 10% of the body surface area. There is mucous 
membrane involvement in approximately 90% of the affected 
patients.
3 The risk factors for SJS include infection, vaccination, 
drugs, systemic diseases, physical agents and food. SJS has been 
associated with more than 100 drugs based on case reports and 
studies.
4
DRESS and SJS are similar in that the clinical manifestations 
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typically occur within 2 to 6 weeks after initiating drug therapy.
1 
However, the two syndromes have different characteristics, 
treatments and prognoses. Here, we compare the causes and 
clinical features of DRESS and SJS.
MATERIALS AND METHODS
Patients and methods
Records of the patients who were hospitalized with a diagno-
sis of DRESS or SJS from April 2004 to March 2008 were re-
viewed. The diagnosis of DRESS or SJS was based on the pres-
ence of a relationship between drug intake and the time to cu-
taneous adverse reactions. Moreover, the diagnosis of DRESS 
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was based on the existence of associated systemic involvement 
and the presence of eosinophilia (>500/mm
3 or >10%).
5,6 The 
diagnosis of SJS was based on severe skin lesions (mucous 
membrane erosions, target lesions and epidermal necrosis with 
skin detachment) affecting less than 10% of the total body sur-
face, regardless of the laboratory findings. The diagnosis was 
confirmed by a histopathological analysis of focal tissue (vacu-
olization of basal layer keratinocytes associated with lympho-
cytes).
5,7,8
DRESS and SJS are differentiated by the nature of the skin le-
sions and extent of body surface area involvement over other 
criteria. Considering an appropriate differential diagnosis in 
patients with mucocutaneous erosions can help prevent misdi-
agnoses associated with cutaneous adverse drug reactions.
Statistics
Statistical analysis was performed using SPSS version 17.0 for 
Windows (SPSS, Chicago, IL, USA). Data are expressed as the 
mean and standard error of the mean. Fisher’s exact test and 
the Mann-Whitney U-test were used for categorical and contin-
uous variables, respectively. Personal characteristics and dis-
ease-related factors were compared between the disorders. The 
association of laboratory tests with the two disorders was ad-
justed for the 95% confidence interval as the effect measure. A 
P value of less than 0.05 was considered statistically significant.
RESULTS
Patient characteristics
The study included 31 adults hospitalized with a diagnosis of 
DRESS or SJS. Eleven patients (4 men, 7 women; median age 51.5 
years) had DRESS and 20 patients (12 men, 8 women; median 
age of 58.5 years) had SJS. There were no significant differences 
in the baseline values between the two disorders (Table 1).
Clinical findings
For DRESS syndrome, patients had prodromal symptoms of 
itching, fever and facial edema. Patients with SJS commonly 
had prodromal symptoms of fever and malaise. The first skin 
lesions appeared on the extremities and face in DRESS and on 
the trunk in SJS (Table 2). The trunk lesions in SJS were tender. 
The mucosal membranes of the oral cavity and eyes were com-
monly affected in SJS. The genitalia (2/19, 10.5%) and anus (2/19, 
10.5%) were also affected (Table 3A).
The results of laboratory tests
The liver was involved in DRESS, and all patients with DRESS 
had elevated liver enzymes. The kidneys (2/11, 18.2%) were also 
involved (Table 3B).
In differentiating between DRESS and SJS, the skin lesions are 
considered first. Two patients with SJS had eosinophilia (>500/
mm
3 or >10%) and 17 had elevated liver enzymes (ALT or AST 
>40 U/L).
Causative drugs
The most common causative drugs were antibiotics, which 
were identified as the cause in 4 of 11 patients (36%) with 
DRESS and 8 of 20 patients (40%) with SJS. From most to least 
common, the four antibiotics that were involved most frequent-
ly were vancomycin, ceftriaxone, rifampin, ciprofloxacin and 
Bactrim. Anticonvulsants were the second most common drugs 
involved; 3 (27%) cases of DRESS and 7 (35%) of SJS were asso-
ciated with anticonvulsants. From most to least common, the 
four anticonvulsants that were involved most frequently were 
lithium, carbamazepine, lamotrigine and oxcarbazepine. The 
remaining drugs involved in both disorders were herbal medi-
Table 1.  Clinical characteristics of study subjects
DRESS SJS P value
Male, n (%) 7 (63.6) 12 (60.0)
Malignancy, n (%) 3 (27.3) 7 (35.0)
Age, median, year (range) 51.0 (15-72) 58.5 (23-82) 0.92
Heart rate, /min (range) 99.0 (54-128) 101.0 (65-134) 0.87
Serum blood urea nitrogen, mg/dL±SEM 15.9±2.68 16.9±1.82 0.65
Serum glucose, mg/dL±SEM 137.9±13.87 133.3±12.83 0.92
Serum bicarbonate, mmol/L±SEM 22.8±1.81 22.4±1.45 0.91
Table 2.  Clinical data
DRESS SJS
Prodromal symptoms, n (%)
Fever
Facial edema
Malaise
Urticaria
5 (45.5)
2 (18.2)
2 (18.2)
8 (72.7)
13 (65.0)
5 (25.0)
11 (55.0)
7 (35.0)
Area of first skin lesions, n (%)
Extrimity
Face
Trunk
Back
7 (63.6)
6 (54.5)
5 (45.5)
2 (18.2)
7 (35.0)
4 (20)
9 (45)
5 (25.0)Allergy Asthma Immunol Res. 2010 April;2(2):123-126.  doi: 10.4168/aair.2010.2.2.123
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cations (10%), allopurinol, clopidogrel and sulfonamide. In ad-
dition, dapsone (18%) and NSAIDs were associated with the 
development of DRESS (Table 4).
Treatment and outcome
Patients with DRESS with internal organ involvement were 
treated with corticosteroids (7 patients, 64%) and dramatic im-
provement was observed. Most patients recovered in the ab-
sence of specific treatment after eliminating the causative drug. 
Most patients with SJS were successfully treated conservatively 
or with corticosteroids. Six patients (30%) were treated with an-
tibiotics and one patient relapsed and died.
DISCUSSION
This study compared the causes and clinical features of DRESS 
and SJS. DRESS is a major cause of hospitalization for dermato-
logical complications in patients treated with anticonvulsants.
10 
The clinical manifestations typically occur within 2 to 6 weeks 
after initiating drug therapy and most cases resolve without se-
quelae when the drug is discontinued. The outcome is fatal in 
5-10% of cases. The most common clinical presentation of 
DRESS includes fever, eruption and lymphadenopathy. The 
most common hematological abnormalities are eosinophilia, 
leukocytosis and lymphocytosis. Liver involvement in patients 
with DRESS may range from a transitory increase in liver en-
zymes to liver necrosis with fulminant hepatic failure. Only 
transitory hepatitis was observed in our study, and the patients 
recovered without sequelae. Other potentially fatal complica-
tions are hypersensitivity myocarditis, pericarditis, pneumoni-
tis and nephritis.
6,11,12
Although there are a variety of etiologies, such as infections 
and underlying malignancies, drugs remain the predominant 
cause of SJS. The most commonly implicated drugs are anti-
convulsants, sulfa derivatives, NSAIDs, penicillins, cepha-
losporins and allopurinols.
1,9 The characteristic skin lesions 
seen in SJS are diffuse erythematous macules with purpuric, 
necrotic centers, and overlying blistering. These cutaneous le-
sions often demonstrate a positive Nikolsky sign, which is fur-
ther detachment of the epidermis with slight lateral pressure. 
Painful erosions of the mucous membranes are common and 
may affect the lips, oral cavity, conjunctiva, nasal cavity, ure-
thra, vagina, gastrointestinal tract and respiratory tract during 
the course of the illness. The mucosal membranes most often 
affected in our study were the oral cavity and eyes. SJS is fatal in 
5-15% of cases.
3,8 Both the incidence of the condition and the 
associated mortality appear to be increased in immunocom-
promised patients.
DRESS and SJS are part of a spectrum of adverse cutaneous 
drug reactions. However, the pathophysiology of DRESS and 
SJS has not been elucidated fully. Various theories have been 
proposed, including both immunological and non-immuno-
logical mechanisms.
3,13 The current pathophysiological expla-
nation for DRESS is immunological. Drugs with reactive me-
tabolites can modify cellular proteins and target an autoim-
Table 3.  Mucosal involvement in SJS and systemic manifestations in DRESS 
syndrome
(A)
Mucosal involvement SJS 
Oral cavity, n (%) 17 (89.5)
Eyes, n (%) 17 (89.5)
Genitalia, n (%) 2 (10.5)
Anus, n (%) 2 (10.5)
(B)
Systemic involvement DRESS 
Nephritis, n (%) 2 (18.2)
Adenopathy, n (%) 2 (18.2)
Hepatitis, n (%) 11 (100)
Eosinophilia, n (%) 11 (100)
Table 4.  Causative drugs
(A) DRESS
Drugs n (%)
Antibiotics 4 (37)
Vancomycin
Ciprofloxacin
Ceftriaxon
2
1
1
Anticonvulsants 3 (27)
Lithium
Carbamazepine
Lamotriagine,
1
1
1
Etc. 4 (37)
Ibuprofen, dapsone, carvediol, allopurinol 4
(B) SJS
Drugs n (%)
Antibiotics 8 (40)
Vancomycin
Ciprofloxacin
Ceftriaxon
Rifampin
Bactrim
2
2
2
1
1
Anticonvulsants 7 (35)
Lithium
Carbamazepine
Oxcarbazepin
3
3
1
Etc. 5 (25)
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mune response against the skin or liver cells.
11 It now appears 
that the immunological mechanisms associated with SJS are 
initiated by the Fas antigen, a cell surface molecule that can 
mediate apoptosis.
3
Laboratory testing can help to identify internal organ involve-
ment, which may not be evident clinically. A skin biopsy may 
help to confirm the diagnosis, but is usually not specific. The 
suspected drug should be discontinued immediately when 
these two syndromes are being considered.
1,8,12 Delaying this 
measure may be associated with a poor outcome. For patients 
with extensive mucocutaneous involvement, prompt referral to 
a burn unit is recommended.
Corticosteroids remain the agents most widely used for treat-
ing DRESS, although the doses used vary widely across case re-
ports.
8 Favorable results have been reported with their use. In 
the absence of a well-established therapy, primary and second-
ary prevention have key roles in the management of these two 
syndromes.
1,8 Milder cases of SJS can be managed in an inpa-
tient setting using the same fundamental therapeutic protocol 
used for the treatment of burns. The use of medications to treat 
SJS remains controversial. Treatment with corticosteroids, while 
effective in most other acute inflammatory disorders, is contro-
versial.
The most important diagnostic clues are the mucosal lesions 
and eosinophilia, characteristic of both syndromes. Age and 
gender were not helpful in differentiating SJS from DRESS. Ele-
vated liver enzymes suggest the DRESS syndrome, well known 
to affect internal organs. As in a previous study, the liver was 
commonly involved in our DRESS patients. However, some ear-
lier studies reported that up to 75% of the patients with SJS had 
elevated liver enzymes, similar to patients with DRESS.
14 Hepa-
titis was observed in 85% of the patients with SJS in our study. 
Anticonvulsants were once the most common cause although, 
more recently, antibiotics have been reported to be the most 
common cause of both disorders.
6,8,9 The increase in the use of 
antibiotics in Korea might explain this finding. After prompt 
withdrawal of the offending drug, conservative treatment or 
combination corticosteroid treatment has been used to treat 
patients with both syndromes, and most patients have im-
proved clinical symptoms and laboratory findings with this ap-
proach. In the absence of specific treatment, the elimination of 
the causative drug and proper symptomatic treatment are the 
best management approaches for both SJS and DRESS.
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